Evidence map›Paper›PMID 30945378›Full record

ArticleTropical medicine & international health : TM & IH2019

Growth in the first 5 years after antiretroviral therapy initiation among HIV-infected children in the IeDEA West African Pediatric Cohort.

Julie Jesson, Ayoko Ephoevi-Ga, Sophie Desmonde, Marie-Hélène Ake-Assi, Marcelline D'Almeida, Haby Signaté Sy, Karen Malateste, Madeleine Amorissani-Folquet, Fatoumata Dicko, Kouakou Kouadio and 3 more

Abstract read
In one paragraph

Article in Tropical medicine & international health : TM & IH, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Julie JessonInserm U1027, Université Paul Sabatier Toulouse 3, Toulouse, France.
Ayoko Ephoevi-GaCHU Tokoin, Lomé, Togo.
Sophie DesmondeInserm U1027, Université Paul Sabatier Toulouse 3, Toulouse, France.
Marie-Hélène Ake-AssiService Pédiatrie, CHU Yopougon, Abidjan, Côte d'Ivoire.
Marcelline D'AlmeidaCNHU Hubert K. Maga, Cotonou, Bénin.
Haby Signaté SyHôpital des Enfants Albert Royer, Dakar, Sénégal.
Karen MalatesteInserm U1219, Bordeaux Population Health Center, Université de Bordeaux, Bordeaux, France.
Madeleine Amorissani-FolquetService Pédiatrie, CHU Cocody, Abidjan, Côte d'Ivoire.
Fatoumata DickoHôpital Gabriel Touré, Bamako, Mali.
Kouakou KouadioCIRBA, Abidjan, Côte d'Ivoire.
Lorna RennerKorle Bu Hospital, Accra, Ghana.
Valériane LeroyInserm U1027, Université Paul Sabatier Toulouse 3, Toulouse, France.
IeDEA West African Pediatric Collaboration

Funding

WADA (West Africa Database on Antiretroviral Therapy) CollaborationU01AI069919 · NIAID · UNIVERSITY OF BORDEAUX II · PI Didier Koumavi Ekouevi, Antoine Jaquet · 2006 to 2026
$29.9M
NIAID NIH HHS U01 AI069919NIH HHS U01AI069919
6 · The paper itself

Abstract

objectiveTo describe growth evolution and its correlates in the first 5 years of antiretroviral therapy (ART) initiation among HIV-infected children followed up in West Africa.

methodsAll HIV-infected children younger than 10 years followed in the IeDEA pWADA cohort while initiating ART, with at least one anthropometric measurement within the first 5 years of treatment were included in the study. Growth was described according to the WHO child growth standards, using Weight-for-age Z-score (WAZ), Height-for-age Z-score (HAZ) and Weight-for-Height/BMI-for-age Z-score (WHZ/BAZ). Growth evolution and its correlates, measured at ART initiation, were modelled in individual linear mixed models for each anthropometric indicator, with a spline term added at the 12-, 24- and 9-month time point for WAZ, HAZ and WHZ/BAZ, respectively.

resultsAmong the 4156 children selected (45% girls, median age at ART initiation 3.9 years [IQR interquartile range 1.9-6.6], and overall 68% malnourished at ART initiation), important gains were observed in the first 12, 24 and 9 months on ART for WAZ, HAZ and WHZ/BAZ, respectively. Correlates at ART initiation of a better growth evolution overtime were early age (<2 years of age), severe immunodeficiency for age, and severity of malnutrition.

conclusionsGrowth evolution is particularly strong within the first 2 years on ART but slows down after this period. Weight and height gains help to recover from pre-ART growth deficiency but are insufficient for the most severely malnourished. The first year on ART could be the best period for nutritional interventions to optimize growth among HIV-infected children in the long-term.

Indexed as

Child DevelopmentAfrica, WesternAnthropometryAnti-HIV AgentsChildChild, PreschoolCohort StudiesDatabases, FactualFemaleGrowth DisordersHIV InfectionsHumansInfantInfant, NewbornLinear ModelsMaleAnti-HIV Agentsantiretroviral therapychildcroissanceenfantgrowthHIVmalnutritiontraitement antirétroviralVIH

Identifiers

PMID30945378
PMCPMC6546509

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.